Abstract
A methylator-resistant human glioblastoma multiforme xenograft, D-245 MG (PR), in athymic nude mice was established by serially treating the parent xenograft D-245 MG with procarbazine. D-245 MG xenografts were sensitive to procarbazine, temozolomide, N-methyl-N-nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea, 9-aminocamptothecin, topotecan, CPT-11, cyclophosphamide, and busulfan. D-245 MG (PR) xenografts were resistant to procarbazine, temozolomide, N-methyl-N-nitrosourea, and busulfan, but they were sensitive to the other agents. Both D-245 MG and D-245 MG (PR) xenografts displayed no O6-alkylguanine-DNA alkyltransferase activity, and their levels of glutathione and glutathione-S-transferase were similar. D-245 MG xenografts expressed the human mismatch repair proteins hMSH2 and hMLH1, whereas D-245 MG (PR) expressed hMLH1 but not hMSH2.
Footnotes
-
↵1 This work was supported by NIH Grants CA 23099, CA 16783, CA 71627, NS 30245, NS 20034, and GM 45190.
-
↵2 To whom requests for reprints should be addressed, at Duke University Medical Center, Department of Pediatrics, Box 3624, Durham, NC 27710, Phone: (919) 684-8722; Fax: (919) 684-8918.
- Received January 23, 1997.
- Accepted May 7, 1997.
- ©1997 American Association for Cancer Research.
Volume 57, Issue 14
